What is Harrow's market cap?

Harrow (HROW) has a market capitalization of $1.4B and trades on NASDAQ.

What is Harrow's revenue and profitability?

Harrow generated $268.7M in trailing twelve-month revenue with a net loss of $39.4M, representing a net margin of -19.8%. Gross margin stands at 74.1%, with free cash flow of $15.3M. These figures are based on the Q1 2026 filing.

Who are Harrow's competitors?

Harrow's key competitors include Bausch + Lomb Corporation, AbbVie Inc., Alcon Inc., and others. These companies compete in similar markets and product categories.

Who does Harrow partner with?

Harrow's notable partners include Apotex Inc., Samsung Bioepis.

What subsidiaries does Harrow have?

Harrow's subsidiaries include Melt Pharmaceuticals, Inc., Surface Ophthalmics, Inc., ImprimisRx.

Where is Harrow headquartered?

Harrow is headquartered in United States of America and employs approximately 382 people. It has been publicly traded since 2007.

HRO

Harrow

HROW

Harrow, Inc. is a leading ophthalmic disease management company focused on the development, production, and sale of innovative medications for eye care professionals in North America.

Market cap

$1.4B+16.4%

Revenue$268.7M+26.2%

Net income-$39.4M-17.8%

Free cash flow$15.3M+892%

EPS (diluted)-$1.08-13.7%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 11, 2026

Revenue$44.2MMiss by $8.2M EPS-$0.74Miss by $0.31

Read the full report

Next report

Aug 10, 2026 (In 1 week)

Revenue estimate$70.4M

EPS estimate-$0.23

Financials

Q1 2026

Income statement

See full

Revenue$44.2M-7.6%

Gross profit$27.0M-16.3%

Operating income-$22.1M-96.6%

Net income-$27.6M-55.2%

EPS (diluted)-$0.74-48.0%

Balance sheet

See full

Cash & equivalents$94.6M+41.8%

Total debt$308.6M-32.9%

Total equity$28.7M-49.1%

Total assets$419.5M+15.2%

Cash flow

See full

Operating cash flow-$9.0M-146%

CapEx$194.0K+14.1%

Free cash flow-$9.2M-147%

Valuation & ratios

Valuation

See full

Market cap$1.4B+16.4%

Enterprise value$1.61B-4.1%

P/S5.2×-0.4×

Profitability

See full

Gross margin74.1%-0.4pp

Operating margin7.3%+5.2pp

FCF margin5.7%+5.0pp

Returns & leverage

See full

Debt / equity10.7×+2.6×

Current ratio2.5×+1.6×

Segments

By product

See full

VEVYE$20.9M-2.6%

Other Products$7.8M+719%

IHEEZO$1.9M-64.6%

Other Revenues$73.0K—

By segment

See full

Branded$30.7M+10.5%

Compounding$13.5M-32.7%

Competitors

By market cap

AbbVie$453.91B+36.3%

Alcon$32.8B-26.4%

Bausch + Lomb$5.8B+13.7%

Ocular Therapeutix$1.9B-1.7%

HRO

Harrow$1.4B+9.1%

Eton Pharmaceuticals, Inc.$1.2B+188%

Opko Health$936.3M-12.5%

LENZ Therapeutics, Inc.$178.7M-79.8%

By revenue growth

Eton Pharmaceuticals, Inc.+79.9%

HRO

Harrow+26.2%

AbbVie+9.5%

Bausch + Lomb+7.9%

Opko Health-11.5%

Ocular Therapeutix-12.8%

By net margin

AbbVie5.79%-1.5pp

Bausch + Lomb-4.21%+3.3pp

Eton Pharmaceuticals, Inc.-9.5%+2.7pp

Opko Health-12.4%+14.3pp

HRO

Harrow-19.75%+1.0pp

Ocular Therapeutix-558.24%-235pp

Profile

Harrow, Inc. is a leading ophthalmic disease management company focused on the development, production, and sale of innovative medications for eye care professionals in North America. The company provides a comprehensive portfolio of FDA-approved branded pharmaceuticals and customized compounded formulations to treat conditions such as dry eye disease, glaucoma, and cataracts. Its value proposition centers on enhancing patient compliance and clinical outcomes through accessible and affordable ophthalmic solutions.

Competitive position

Harrow maintains a leading position in the North American ophthalmic market by bridging the gap between high-volume compounded medications and specialized FDA-approved branded therapies.

GeographiesUnited States, Canada

Customer segmentsHealthcare Providers, Surgical Centers, Retail Patients

Business modelManufacturing, Licensing, Direct Sales, B2B

SuppliersContract Manufacturing Organizations (CMOs), Active Pharmaceutical Ingredient (API) suppliers, Third-party logistics providers

CustomersOphthalmology clinics, Ambulatory surgery centers, Hospitals, Retail pharmacies, Government healthcare programs (Medicare/Medicaid)

CountryUnited States of America

Listed2007

Employees382.0

CEOMark L. Baum

SectorHealthcare

IndustryMedical - Pharmaceuticals

Websiteharrow.com

FilingsSEC EDGAR

Ask your AI about Harrow.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Harrow's market cap?: Harrow (HROW) has a market capitalization of $1.4B and trades on NASDAQ.
What is Harrow's revenue and profitability?: Harrow generated $268.7M in trailing twelve-month revenue with a net loss of $39.4M, representing a net margin of -19.8%. Gross margin stands at 74.1%, with free cash flow of $15.3M. These figures are based on the Q1 2026 filing.
Who are Harrow's competitors?: Harrow's key competitors include Bausch + Lomb Corporation, AbbVie Inc., Alcon Inc., and others. These companies compete in similar markets and product categories.
Who does Harrow partner with?: Harrow's notable partners include Apotex Inc., Samsung Bioepis.
What subsidiaries does Harrow have?: Harrow's subsidiaries include Melt Pharmaceuticals, Inc., Surface Ophthalmics, Inc., ImprimisRx.
Where is Harrow headquartered?: Harrow is headquartered in United States of America and employs approximately 382 people. It has been publicly traded since 2007.